PFE.NEO Pfizer CDR (CAD Hedged)
- Market cap
- CAD 231B
- P/E
- 16.3x
- P/B
- 1.81x
- ROE
- 5.7%
- Dividend yield
- 6.79%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PFE.NEO undervalued?
Graham numberPFE.NEO trades 14.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pfizer CDR (CAD Hedged) fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (5.7%), below 10%.
ROA 0/1
Return on assets (2.4%) is below the industry median (3.8%).
Profit Consistency 2/2
Profitable for 8 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-3.6%) is not above the 5-year average (-4.6% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-3.6%) is below the industry median (14.7%).
Revenue Growth 0/2
Revenue shrank 14.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (71.0%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.9x against interest expense, below 5x.
PE vs Market 1/1
PE (16.6x) is below the market median (20.3x).
PE vs Industry 1/1
PE (16.6x) is below the industry median (16.6x).
PBV 0/1
Price to book (1.8x) is above the industry median (1.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 30.5, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (7.6%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 8 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
Payout ratio is 125.7%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Pfizer CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pfizer CDR (CAD Hedged)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-…
Full company profilePfizer CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pfizer CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 53.6B | 51.8B | 41.9B | 81.3B | 100B | 59.6B | 63.6B | 62.6B | 59.0B |
| Gross Profit | 42.4B | 41.5B | 33.2B | 50.5B | 66.0B | 34.6B | 45.8B | 46.5B | 43.7B |
| Operating Income | 15.0B | 13.9B | 8.76B | 20.2B | 37.3B | 4.42B | 14.9B | 17.4B | 15.6B |
| EBITDA | 19.6B | 25.3B | 13.7B | 30.8B | 39.6B | 9.56B | 18.1B | 16.8B | 14.2B |
| Net Income | 11.2B | 16.3B | 9.62B | 22.0B | 31.4B | 2.12B | 8.03B | 7.77B | 4.88B |
| EPS | 1.95 | 2.94 | 1.73 | 3.91 | 5.59 | 0.38 | 1.42 | 1.37 | 0.86 |
| Balance Sheet | |||||||||
| Total Assets | 159B | 167B | 154B | 181B | 197B | 227B | 213B | 208B | 201B |
| Total Liabilities | 95.7B | 104B | 90.8B | 104B | 101B | 137B | 125B | 121B | 116B |
| Shareholders' Equity | 63.4B | 63.1B | 63.2B | 77.2B | 95.7B | 89.0B | 88.2B | 86.5B | 85.2B |
| Cash & Short-term Investments | 1.14B | 1.31B | 1.78B | 1.94B | 416M | 2.85B | 1.04B | 1.14B | 976M |
| Cash Flow | |||||||||
| Operating Cash Flow | 15.8B | 12.6B | 14.4B | 32.6B | 29.3B | 12.0B | 12.7B | 11.7B | 6.90B |
| Capital Expenditure | 1.98B | 2.05B | 2.23B | 2.71B | 3.24B | 3.86B | 2.91B | 2.63B | 1.94B |
| Free Cash Flow | 13.6B | 9.99B | 11.6B | 29.9B | 26.0B | 8.18B | 9.84B | 9.08B | 4.96B |
| Ratios | |||||||||
| ROE | 17.6% | 25.8% | 15.2% | 28.5% | 32.8% | 2.4% | 9.1% | 9.0% | 5.7% |
| ROA | 7.0% | 9.7% | 6.2% | 12.1% | 15.9% | 0.9% | 3.8% | 3.7% | 2.4% |
| Net Profit Margin | 20.8% | 31.4% | 22.9% | 27.0% | 31.3% | 3.6% | 12.6% | 12.4% | 8.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pfizer CDR (CAD Hedged) dividends
- Dividend yield
- 6.79%
- Forward dividend
- 0.78 CAD
- Payout ratio
- 125.7%
- Ex-dividend date
- Jan 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 9.77B | 1.72 | 125.7% |
| 2024 | USD 9.51B | 1.68 | 118.4% |
| 2023 | USD 9.18B | 1.63 | 433.1% |
| 2022 | USD 8.98B | 1.60 | 28.6% |
| 2021 | USD 8.73B | 1.55 | 39.7% |
| 2020 | USD 8.44B | 1.52 | 87.8% |
| 2019 | CAD 8.04B | 1.45 | 49.4% |
| 2018 | CAD 7.98B | 1.40 | 71.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Pfizer CDR (CAD Hedged)
Ownership data of Pfizer CDR (CAD Hedged) is not available yet.
Pfizer CDR (CAD Hedged) company profile
- Company name
- Pfizer CDR (CAD Hedged)
- Ticker
- PFE.NEO
- ISIN
- CA7170651060
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 81,000
- Fiscal year end
- December
- Address
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
- Phone
- 212 733 2323
- Website
- pfizer.com
About Pfizer CDR (CAD Hedged)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer CDR (CAD Hedged) management
10- Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · born 1962
- Mr. David M. DentonExecutive VP & CFO · born 1965
- Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · born 1964
- Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · born 1976
- Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · born 1968
- Ms. Lidia L. FonsecaExecutive VP and Chief Digital & Technology Officer · born 1969
- Ms. Francesca M. DeMartinoChief Investor Relations Officer
- Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · born 1966
- Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · born 1975
- Ms. Sally M. SusmanExecutive VP & Chief Corporate Affairs Officer · born 1962